Brian Gallagher
Partner @ Abingworth
Cambridge, United States
Brian Gallagher is a Series A investor at Abingworth in Cambridge focused on Therapeutics and Biotechnology. Brian Gallagher - Partner @ Abingworth
- Total investments:
- 8
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Brian Gallagher invests in
Stages Brian Gallagher invests in
Countries Brian Gallagher invests in
Investment Focus
Industry
- Therapeutics 2 (25%)
- Biotechnology 2 (25%)
- Medical 1 (13%)
- Genetics 1 (13%)
- Wellness 1 (13%)
Stage
- Series A 1 (13%)
- Series B 1 (13%)
- Series D 1 (13%)
- Series E 1 (13%)
- Series F 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Constellation Pharmaceuticals
|
Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression. | $100M / Series F / Apr 09, 2018 | |
Aileron Therapeutics
|
Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. | $33M / Series E / Oct 29, 2014 | |
|
Aileron Therapeutics
|
Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. | $30M / Series E / Nov 18, 2013 | |
|
Aileron Therapeutics
|
Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. | $12M / Series D / Jan 14, 2013 | |
River Vision Development
|
River Vision Development develops RV001, a protein therapy for the treatment of Graves’ Orbitopathy (GO). River Vision Development was founded in 2011 and is based in New York, New York. | $17M / Series A / Dec 12, 2012 | |
|
Constellation Pharmaceuticals
|
Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression. | $15M / Series B / Jun 06, 2011 | |
|
Constellation Pharmaceuticals
|
Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression. | $22.3M / Series B / Jun 07, 2010 | |
|
Aileron Therapeutics
|
Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. | $40M / Series D / Jun 11, 2009 |
Co-Investors
About Abingworth
Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciencessectors.Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park, and Boston, Abingworth has invested in 142 life science companies, completed 60 IPOs and 40 mergers and acquisitions.
Abingworth Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Brian Gallagher
Partner
|
|||
John Shields
Advisor, Science and Technology
|
|||
Quentin Lloyd-Harris
Partner
|
|||
Alex Asquith
General Counsel and Chief Financial Officer
|
|||
Andrew Sinclair
Partner & Portfolio Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Brian Gallagher invest in?
Brian Gallagher invests primarily in Therapeutics, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
